Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic uro...
locally-advanced-uc-treatment
As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda, Merck) for people who have locally advan...
locally-advanced-uc-treatment